petition. 10 -13 Such trans-repression mechanism is likely to explain the anti-inflammatory actions of PPARs (see review 10 ).
The PPAR transcriptional pathway is controlled by the following: the level of receptor expression and stability; its posttranslational modifications, ligand specificity, and availability; and cofactor recruitment ( Figure 1 ).
Although PPAR␣ is expressed preferentially in tissues in which FAs are catabolized, PPAR␥ is present in adipose tissue, mammary glands, and numerous other tissues, and PPAR␤/␦ is ubiquitously expressed (see review 2 ). The expression levels of PPARs are modulated by stimuli as varied as circadian rhythm, 14 fasting, 15, 16 stress, 14 and cold. 17 Furthermore, various factors, such as corticosteroids, 18, 19 insulin, 18, 20 phorbol esters, and different cytokines, 21 affect PPAR expression. Additionally, PPAR and retinoid X receptor ligands also modulate PPAR mRNA levels. 22, 23 PPAR protein levels are also subject to regulation. Although thiazolidinediones (TZDs) were shown to induce PPAR␥ receptor ubiquitination and subsequent degradation by the proteasome, 24 fibrates inhibit PPAR␣ ubiquitination and increase PPAR␣ protein half-life. 25, 26 PPAR␣ and PPAR␥ are phosphoproteins, and their phosphorylation status affects their transcriptional activity. 27 For instance, Hansen et al 28 reported that the cAMP signaling pathway, most likely via protein kinase A, increases PPAR␤/␦-mediated transactivation.
The ligand dependence of PPAR activity renders the availability of an activator an important regulator of receptor function. In that way, albumin, which sequesters PGJ 2 , controls the activity of PPAR␥. 29 Similarly, ligand binding to FA-binding proteins (FABPs) has been proposed as a mechanism of intracellular transport of PPAR agonists from the cytoplasm to the nucleus, thus modulating the activation of the receptor. 30 Upon binding, different ligands induce distinct conformations of the receptor, leading to differential coactivator recruitment (see review 27 ) and, consequently, differential biological responses. 31, 32 These observations are at the basis of the "selective PPAR modulator" concept. 33 
PPARs and Dyslipidemia
The dyslipidemia associated with the metabolic syndrome is characterized by elevated plasma levels of triglycerides and small dense LDL particles and decreased HDL cholesterol. In vivo and in vitro data demonstrate that PPARs play a central role in the control of FA and lipoprotein metabolism.
Role of PPARs in Triglyceride and LDL Metabolism
In rodents, the central role of PPAR␣ in FA metabolism under feeding/fasting conditions has been clearly demonstrated. 15, 16 On severe fasting, PPAR␣ activity and expression are induced, allowing the catabolism of FAs to produce ketone bodies, which serve as energy sources for extrahepatic tissues. In humans, pharmacological PPAR␣ activation with fibrates decreases plasma triglyceride concentrations by acting on different metabolic pathways. 34 Fibrates increase FA uptake and catabolism, resulting (as a consequence) in limited triglyceride and VLDL production by the liver 34 (Figure 2 ). Simultaneously, these hypolipidemic drugs enhance intravascular triglyceride metabolism.
The intracellular concentration of FAs is partly controlled by the regulation of their cellular uptake, which is mediated through different transporters, such as FA transport protein 1 (FATP1) and FA translocase (FAT/CD36). Fibrate treatment induces FATP1 and FAT mRNA levels in rodent liver, whereas glitazones induce the expression of these genes in white adipose tissue. 35, 36 In addition, the expression of the intracellular FABP, L-FABP, is regulated by fibrates in the liver. 37 Interestingly, PPAR␣ agonists failed to modulate L-FABP expression in the small intestine, whereas PPAR␣-null mice treated with a novel PPAR␤/␦-PPAR␣-specific agonist (GW2433) display an increase in L-FABP expression in this tissue, 38 indicating that PPAR␤/␦ also regulates the expression of genes involved in FA metabolism. However, the physiological consequences of this regulation are presently unclear.
Intracellular FA flux is regulated by key proteins, ie, acyl coenzyme A synthetase (ACS), which catalyzes the esterification of FAs, thus favoring their cellular retention. By modulating the expression of ACS, PPAR␣ and PPAR␥ polarize FA fluxes. 39 Furthermore, PPAR␣ induces FA uptake and catabolism in mitochondria via stimulation of muscle and liver carnitine palmitoyltransferase I and II 40 -43 and several mitochondrial FA-catabolizing enzymes. 44 When mitochondrial FA import is inhibited in male PPAR␣-null mice, massive cardiac and hepatic lipid accumulation and hypoglycemia are observed. 45 This inhibition provokes a feedback upregulation of PPAR␣ target genes in wild-type, but not in PPAR␣-null, mice. 45 PPAR␣ controls mitochondrial hydroxymethylglutaryl coenzyme A synthase expression and, thus, promotes ketone body synthesis. 46, 47 In rodent, but not in human, hepatocytes, PPAR␣ induces the expression of various enzymes involved in peroxisomal ␤-oxidation. 34, 47 Intravascular lipolysis activity is controlled by the activity of lipoprotein lipase (LPL). Fibrate-activated PPAR␣ controls LPL activity by inducing its expression in the liver and by inhibiting the hepatic expression of apoC-III, an LPL activity and remnant catabolism inhibitor. 48 -50 These effects promote lipolysis and triglyceride-rich lipoprotein catabolism, thus decreasing the plasma levels of triglycerides. The role of PPAR␣ on circulating VLDL levels is demonstrated in vivo in PPAR␣-null/apoE-null mice, which display higher VLDL production on high-fat diet feeding than do control mice. 51 Glitazones also affect the circulating levels of free FAs, cholesterol, and triglycerides. In obese animal models, TZDs and non-TZD glitazones decrease the circulating levels of triglycerides by inducing lipolysis (via activation of LPL expression in adipocytes) and clearance of triglyceride-rich lipoproteins. [52] [53] [54] In rodents, simultaneous administration of PPAR␣ and PPAR␥ activators results in a more efficient hypotriglyceridemic activity, which is likely due to combined actions on liver apoC-III and adipose tissue LPL expression. 55 The induction of LPL by PPAR␥ promotes FA delivery, whereas induction of FATP and ACS results in enhanced FA uptake. These actions contribute to enhanced triglyceride storage in adipose tissue. PPAR␥ also modulates the expression of enzymes involved in the synthesis of FA and triglycerides, such as malic enzyme. 56 Although the triglyceride-lowering activity of PPAR␥ agonists in animal models is well documented, substantial controversy exists concerning their hypotriglyceridemic activity in humans.
PPARs, HDL Metabolism, and the Reverse Cholesterol Transport (RCT) Pathway
The RCT pathway mediates the centripetal transport of cholesterol from peripheral cells back to the liver. Cholesterol from peripheral cells is captured by HDL particles, which transport it back to the liver, where cholesterol is eliminated either directly into the bile or after metabolism in bile acids. PPARs influence the RCT pathway by regulating macrophage cholesterol efflux, HDL cholesterol transport in plasma, and bile acid synthesis ( Figure 3 ).
Cholesterol efflux, the first step of the RCT, occurs either via passive diffusion or via transmembrane transporters, such as the scavenger receptor (SR) class B type 1 (SR-B1/CLA-1) and the ATP-binding cassette A1 (ABCA1) proteins. In human macrophages, PPAR␣ and PPAR␥ activators induce protein levels of SR-B1/CLA-1, 57 whereas ligands of all 3 PPAR isotypes induce the expression of ABCA1. 9, 58, 59 PPAR␣ and PPAR␥ induce ABCA1 by an indirect mechanism via induction of the nuclear liver X receptor (LXR)␣. 58, 59 However, the molecular mechanism of ABCA1 induction by PPAR␤/␦ activators appears to be LXR␣ independent. 9 Increased ABCA1 expression results in a higher cholesterol efflux from macrophages. The major contribution of ABCA1 in the control of plasma HDL cholesterol levels has been highlighted by the identification of mutations in the ABCA1 gene in patients with familial HDL deficiency and Tangier disease.
ApoA-I and apoA-II are the major HDL apolipoproteins. In humans, PPAR␣ increases the transcription of these 2 genes via binding to PPREs in their promoters, 60, 61 an effect that contributes to the increase of HDL concentrations following fibrate treatment. Although the increase of plasma apoA-I is undoubtedly beneficial, substantial controversy exists concerning the role of apoA-II in atherosclerosis. Indeed, whereas transgenic mice overexpressing murine apoA-II are more prone to develop atherosclerosis, 62 overexpression of human apoA-II protects against atherogenesis. 63 PPAR␤/␦-specific agonists also increase plasma HDL cholesterol concentrations in insulin-resistant mice and obese rhesus monkeys. 9, 64 The molecular mechanisms behind this increase remain to be clarified.
Recently, Bouly et al 65 have shown that PPAR␣ agonists induce the expression and activity of the phospholipid trans- fer protein (PLTP), an enzyme catalyzing the transfer of phospholipids from VLDL/LDL to HDL, in mice. PLTP induction contributes to the marked enlargement of HDL in fenofibrate-treated mice. Such action may also be antiatherogenic, since PLTP deficiency results in an enhanced susceptibility to atherosclerosis, which is due to decreased antioxidant transfer to endothelial cells. 66 However, although fibrates influence the expression of HDL-remodeling enzymes, such as PLTP and lecithin-cholesterol acyltransferase, in rat liver, 67 little is known about the regulation of these proteins in humans.
Cholesterol is excreted from the liver into the bile either directly or after conversion into bile acids. The role of PPAR␣ in the control of bile acid synthesis and composition is still unclear and controversial. Whereas PPAR␣ has been shown to induce the hepatic expression of LXR␣, 68 which subsequently upregulates the expression of cholesterol 7␣-hydroxylase (CYP7A1), 69 fibrates reduce the activity of this enzyme in rodents and humans. 70 -72 By contrast, PPAR␣ has been reported as a positive regulator of murine and human CYP7A promoter activity. 73 Thus, the role of PPAR␣ in CYP7A expression and activity is not completely understood. However, activated PPAR␣ induces the expression of cholesterol 12␣-hydroxylase (CYP8B1), an enzyme that determines the lithogenic index (ratio cholic acid versus chenodeoxycholic acid). 74 
PPARs and Atherogenesis
Atherosclerosis is a complex process characterized by lipid accumulation in the arterial wall. Atherogenesis starts with the attraction, recruitment, and activation of different cell types, including monocytes/macrophages, T lymphocytes, endothelial cells, and intimal smooth muscle cells (SMCs). This cellular activation provokes a local inflammatory response. As regulators of lipid and lipoprotein metabolism, PPARs control plasma levels of cholesterol and triglycerides, which constitute major risk factors for coronary heart disease. Clinical studies have shown that fibrates prevent atherosclerotic lesion progression. [75] [76] [77] Although less data are available in humans with respect to glitazones, in rodents, the PPAR␥ ligand troglitazone inhibits SMC proliferation and decreases the intima and media thickness of carotid arteries. 78 PPARs are expressed in most cell types of the vascular wall as well as in atherosclerotic lesions (see review 10 ), where they affect atherogenic processes (Figure 4 ). Figure 4 shows the modulation of atherogenesis and atherothrombosis by PPARs. PPARs regulate chemoattraction and cellular adhesion to endothelial cells (Figure 4 ). PPAR␣ and PPAR␥ activators repress thrombin-induced expression of endothelin-1, a potent vasoconstrictor peptide and inducer of SMC proliferation. 79, 80 Although the expression of monocyte chemoattractant protein (MCP)-1, a chemokine that promotes monocyte chemotaxis, is clearly inhibited by PPAR␥ ligands, 81 the effect of PPAR␣ activators is still unclear. In human aortic endothelial cells, natural and synthetic PPAR␣ ligands stimulate the synthesis of MCP-1. 82 In contrast, Pasceri et al 83 have reported that fibrates reduce C-reactive protein (CRP)-induced expression of MCP-1 in human umbilical vein endothelial cells. PPAR␥ activation blocks endothelial expression of interferon (IFN)-␥-inducible 10-kDa protein, a monokine induced by IFN-␥, and IFN-inducible T-cell ␣-chemoattractant, which are chemokines that promote T-cell recruitment to sites of inflammation. 84 Furthermore, PPARs modulate T-lymphocyte proliferation and immune activation. 85, 86 In monocytes, glitazones decrease the expression of CCR2, the transmembrane receptor for MCP-1. 87 PPAR␣ and PPAR␥ activators reduce cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1. 88, 89 These adhesion molecules play a critical role in the recruitment of leukocytes and monocytes to atherosclerotic lesions. In vivo studies have demonstrated that troglitazone significantly reduces monocyte/macrophage recruitment to atherosclerotic lesions in apoE-null mice. 90 
PPARs Modulate Early Stages of Atherogenesis

PPARs Control Lipid Accumulation Within the Plaque
Although PPARs do not influence macrophage differentiation, they play an important role in regulating cholesterol Figure 3 . PPARs stimulate the reverse cholesterol pathway. PPARs regulate the RCT pathway by modulating macrophage cholesterol efflux and cholesterol transport in plasma and bile acid synthesis. Cholesterol efflux via transmembrane transporters ABCA1 and, possibly, SR-BI is stimulated by PPAR activators in human macrophages. Nascent HDL particles accept cholesterol, which is subsequently esterified by lecithin-cholesterol acyltransferase (LCAT). Fibrates stimulate the expression and activity of the HDL-remodeling enzyme PLTP in rodents. Hepatic SR-BI mediates the uptake of cholesterol esters from HDL in the liver, where cholesterol is excreted into bile either directly or after conversion to bile salts. Genes regulated by PPARs, either directly or indirectly, are indicated by gray background arrows (human genes in plain white and rodent genes in hatched). CETP indicates cholesteryl ester transfer protein; FC, free cholesterol; and EC, esterified cholesterol.
homeostasis in macrophages ( Figure 4 ). As described above, PPAR␣, PPAR␥, and PPAR␤/␦ activators induce the expression of ABCA1 and SR-BI, thus promoting cholesterol efflux from macrophages. By acting through posttranscriptional mechanisms, 91,92 PPAR␥ ligands decrease the protein level of SR-A, which is involved in the uptake of modified LDL. In addition, PPAR␥ agonists induce the expression of CD36, a scavenger receptor for oxidized LDL in macrophages. 91, 92 The net effect is that neither PPAR␣ nor PPAR␥ promotes cholesterol accumulation in macrophages or foam cell formation. 58, 91 In contrast, activation of PPAR␤/␦, whose expression is increased during the differentiation of THP-1-derived human macrophages, increases the expression of genes involved in lipid uptake and storage, such as SR-A and CD36. 93 These results identify PPAR␤/␦ as a potential promoter of macrophage lipid accumulation and suggest a role for PPAR␤/␦ in the pathology of atherosclerosis.
The atheroprotective role of PPAR␥ has been further documented in animal models of atherosclerosis. 7, 94, 95 In male LDL receptor-null mice, rosiglitazone and GW7845 treatment reduces the progression of atherosclerotic lesions and decreases macrophage accumulation in intimal xanthomas. 7, 94 Intriguingly, in these studies, female mice did not exhibit a reduction in atherosclerosis in response to PPAR␥ ligand treatment. 7 This lack of response could be partly explained by the decrease of HDL levels in female mice treated with PPAR␥ ligands. 7 Li et al 7 related these differences to influences of estrogens and progestins, inasmuch as their preliminary studies indicate the metabolic response to rosiglitazone and GW7845 in ovariectomized female mice to be much more similar to that in male mice. In male and female apoE-null mice, troglitazone inhibits fatty steak formation while enhancing HDL cholesterol levels and increasing CD36 mRNA levels in the aorta. 95 Surprisingly, PPAR␣-null/apoE-null mice develop less atherosclerotic lesions than do apoE-null control mice when they are fed a high-fat diet. 51 Furthermore, these double PPAR␣/apoE-knockout mice display higher concentrations of atherogenic lipoproteins, but they also demonstrate higher insulin sensitivity and lower blood pressure. 51 The lower blood pressure in PPAR␣-null animals might contribute to the reduced atherosclerotic lesions observed in these animals, despite the higher levels of atherogenic lipoproteins. In contrast, irradiated LDL receptornull mice reconstituted with bone marrow from PPAR␣-null mice present more atherosclerotic lesions when compared with control mice, suggesting that macrophage PPAR␣ expression inhibits early atherosclerotic lesion formation. 96 Because PPAR␣-null macrophages and aortas present an enhanced production of tumor necrosis factor (TNF)-␣ and interleukin (IL)-6, the inhibitory activity of PPAR␣ on the formation of atherosclerotic lesions may be related to the control of cytokine production during vascular inflammation. 96, 97 
PPARs and the Local Inflammatory Response
The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response (Figure 4 ). Various studies have demonstrated that PPARs inhibit the expression of inflammatory genes, such as cytokines, metalloproteases, and acute-phase reactants (see review 98 ). PPARs exert antiinflammatory activities in different immunological and vascular cell types, such as monocytes/macrophages, endothelial cells, SMCs, dendritic cells, and T lymphocytes.
Incubation of human monocytes with natural (PGJ 2 ) and synthetic PPAR␥ ligands inhibits the production of inflammatory cytokines, such as TNF-␣, IL-1␤, IL-6, IL-8, and IL-10. 99,100 However, most pronounced effects are observed with PGJ 2 , which is not very selective for PPAR␥ and also acts via PPAR-independent mechanisms. 98 Furthermore, certain anti-inflammatory properties of PPAR␥ agonists were observed in PPAR␥-null embryonic stem cell-derived macrophages, albeit at extremely high concentrations. 92 Thus, glitazones and natural PPAR␥ ligands appear to exert antiinflammatory activities via PPAR␥-dependent and -independent mechanisms.
In human aortic SMCs, PPAR␣ activators inhibit the expression of inducible cyclooxygenase-2 and IL-6. 101 In human monocytes/macrophages, PPAR␣ activators inhibit cytokine-induced expression of VCAM-1 and tissue factor (TF). 88, 102, 103 In rat aortic SMCs, PGJ 2 and 9-HODE induce the expression of type II-secreted phospholipase A 2 (type II-sPLA 2 ), an enzyme involved in the hydrolysis of phospholipids. Induced expression of type II-sPLA 2 generates lipid inflammatory mediators, such as lysophosphatidic and arachidonic acids. 104 Type II-sPLA 2 increases lipoxygenase- mediated PPAR agonist (HODE) production from LDL 105 and may initially lead to a PPAR-independent proinflammatory activity, followed by a PPAR-dependent arrest of the inflammatory response. Results from studies using PPAR␣-null mice clearly demonstrate a role for PPAR␣ in the control of the inflammatory response. 80, 106 The anti-inflammatory activities of PPAR␣ and PPAR␥ activators have been evidenced in humans. In patients with mild hyperlipidemia, fenofibrate treatment has been shown to decrease the circulating levels of IL-6 and to lower the plasma levels of various risk factors for cardiovascular disease, such as fibrinogen and CRP, whose production is controlled by cytokines. 83, 101 Similarly, rosiglitazone treatment of patients with type 2 diabetes significantly reduces plasma levels of IL-6 and CRP. 107 
PPARs, Plaque Stability, and Atherothrombosis
Plaque rupture is the end stage of the atherogenic process, leading to thrombus formation, occlusion, and the clinical sequels of atherosclerosis ( Figure 4 ). Plaque instability is partly due to the degradation of the extracellular matrix in the fibrous cap. PPAR␥ activators inhibit the expression of metalloproteinase-9, a secreted matrix-degrading protein. 108 This PPAR␥-dependent inhibition may prevent the rupture of the atherosclerotic plaque and subsequent thrombosis. On the other hand, troglitazone and PGJ 2 inhibit the migration of SMCs, which occurs during atherosclerotic plaque formation. This effect may be due to the inhibition of secretion of metalloproteinases, which contribute to this process. 109 Furthermore, glitazones inhibit vascular SMC (VSMC) expression of Ets-1, a transcription factor regulating matrix metalloproteinase gene transcription. 110 This inhibition results in a decreased VSMC migration within the plaque.
In addition, PPARs also modulate platelet aggregation. PPAR␥ activators inhibit the expression of thromboxane synthase by a mechanism involving protein-protein interaction between PPAR␥ and the nuclear factor-E2-related factor 2. 111 This results in a decreased production of thromboxane A 2 , a potent platelet aggregation inducer. Moreover, the expression of the thromboxane receptor is inhibited by PPAR␥ activators in rat VSMCs. 112 PPAR␣ also inhibits the expression of the platelet-activating factor receptor and TF in human monocytes and macrophages. 102, 103, 113 These actions may result in a decreased thrombogenic response.
Glitazones and fibrates also modulate the secretion of the thrombosis inducer plasminogen activator inhibitor type 1. 114, 115 However, the molecular data are still confusing, 116, 117 and the role of PPARs in the regulation of plasminogen activator inhibitor type 1 and its consequences for atherothrombosis remain to be clarified.
Apoptosis is a major event in the pathophysiology of atherothrombosis. However, the significance of apoptosis in this process is unclear (see review 118 ). PPAR␣ and PPAR␥ control apoptosis via negative cross talk with the antiapoptotic nuclear factor-B pathway in macrophages. 119 Furthermore, PPAR␥ inhibits the mitogenic induction of the cyclindependent kinase inhibitor p21 by modulating the protein kinase C-␦ pathway in VSMCs. 120 In addition, PPAR␥ stimulates the expression of PTEN, a tumor suppressor that modulates the inflammatory response and several cellular functions, including cell migration, survival, and proliferation. 121 However, it remains to be determined whether apoptosis induction by PPARs also occurs in vivo and is of clinical importance.
PPAR Activators in Clinical Practice
A wealth of clinical studies have affirmed that fibrates improve the cardiovascular risk profile. Several angiographic intervention trials, including the Lipid Coronary Angiographic Trial (LOCAT), the Diabetes Atherosclerosis Intervention Study (DAIS), and the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), have demonstrated beneficial effects of fibrates on atherosclerotic lesion progression. [75] [76] [77] Furthermore, secondary prevention trials, such as the Veterans Administration-HDL-Cholesterol Intervention Trial (VA-HIT) 122 and the Helsinki Heart Study, 123 have demonstrated a decreased incidence of cardiovascular events after fibrate treatment. In patients with type 2 diabetes, who are characterized by moderate hypertriglyceridemia and low HDL cholesterol concentrations, fibrates decrease the incidence of myocardial infarction, as observed in the St. Mary's, Ealing, Northwick Park Diabetes (SENDCAP) study. 124 Several studies have been performed testing the effects of glitazone treatment on glucose homeostasis in various diabetic and insulin-resistant patient populations. 125, 126 Glitazone therapy lowers fasting and postprandial glucose levels and improves insulin-stimulated glucose disposal. However, the effect of glitazone on the plasma lipid profile in humans is controversial, and intervention trials assessing the influence of these compounds on the incidence of cardiovascular disease are still lacking. Nevertheless, troglitazone treatment of patients with type 2 diabetes has clearly established this molecule to be a potent inhibitor of early atherosclerotic lesion progression. 127 In patients with type 2 diabetes, pioglitazone and rosiglitazone appear to have distinct effects on the plasma levels of triglycerides and LDL. Although pioglitazone treatment lowers serum concentrations of LDL and triglycerides, rosiglitazone treatment does not appear to lower triglyceride or to increase the levels of LDL cholesterol. 125, 128 Although the mechanistic basis for these difference is unclear, one possible explanation may be that pioglitazone has, albeit limited, PPAR␣ activity. 129 Despite their atheroprotective properties, certain glitazones present a significant risk of hepatotoxicity and heart failure; thus, their clinical use should be carefully monitored. 130 Troglitazone has been withdrawn worldwide because of its hepatotoxic effects. The risk of heart failure with glitazones, which is likely due to plasma volume expansion, is enhanced when they are used in combination therapy with insulin. 130 Running trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and PROACTIVE trials, will provide additional evidence for possible clinical cardiovascular benefits of PPAR␣ and PPAR␥ agonists in the diabetic population.
Conclusions
The intimate and causative relationships between lipid metabolism and coronary heart disease have stimulated research involving the physiological functions of the lipid-activated transcription factors of the PPAR family. This research has resulted in the development and understanding of the action mechanism of drugs useful in the treatment of metabolic disorders predisposing to atherosclerosis. With the use of recently developed potent subtype-specific agonists, it has been demonstrated that all 3 PPARs control lipid metabolism; however, the precise role of PPAR␤/␦ remains to be clarified at the molecular and physiological levels. The next years will be exciting with the prospect of development of novel PPAR agonists, with, for instance, mixed PPAR␣ and PPAR␥ activity. Moreover, it is conceivable that future development of drugs exerting their activity via PPARs will focus not so much on the search of more potent activators but on selective receptor modulators in an attempt to separate desirable from unwanted side effects. Finally, ongoing clinical studies with specific PPAR␣-PPAR␤/␦-PPAR␥ (co)activators should prove (or disprove) their potent activity in reducing coronary events and total mortality.
